Ocugen, Inc.Pembelian
OCUGEN CALLS IDEA!! $7.5 Dec 22
[h1]Best Vaccine pandemic play!![/h1]
Ocugen has just proven to have a vaccine that (Covaxin) can neutralize both Omnicron(most infectious) and the Delta variant(most violent).
Ocugen has seen a beating! Last Quarter the company dropped nearly 50% from previous highs. I'm expecting a return to those highs some time late spring/early summer.
I think $3 is the lowest we can go but, to me its all upside from here! Ocugen could also cause some serious problems for Over- Exposed short sellers.
With T-35 filings piling up and over 25% of the Float in Short interest, this could see a monumental increase in price.
##[h2]The play[/h2]##
Great news behind a great company, professionals have a price target at $10 which is a 110% gain from current levels!!!
My personal Price target is the $20-$25 range.
Recently, I've opened some Dec 22 call options on OCUGEN at $7.5!
Target: 1 | Target: 2 |Target: 3
$11 | $16.50 | $25
Ocugen has just proven to have a vaccine that (Covaxin) can neutralize both Omnicron(most infectious) and the Delta variant(most violent).
Ocugen has seen a beating! Last Quarter the company dropped nearly 50% from previous highs. I'm expecting a return to those highs some time late spring/early summer.
I think $3 is the lowest we can go but, to me its all upside from here! Ocugen could also cause some serious problems for Over- Exposed short sellers.
With T-35 filings piling up and over 25% of the Float in Short interest, this could see a monumental increase in price.
##[h2]The play[/h2]##
Great news behind a great company, professionals have a price target at $10 which is a 110% gain from current levels!!!
My personal Price target is the $20-$25 range.
Recently, I've opened some Dec 22 call options on OCUGEN at $7.5!
Target: 1 | Target: 2 |Target: 3
$11 | $16.50 | $25
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.